Cargando…

Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data

BACKGROUND: The median age at renal cell carcinoma (RCC) diagnosis is 64 years. However, few studies have assessed the real-world time on treatment (TOT), health resource utilization (HRU), costs, or treatment compliance associated with targeted therapy use among patients in this age group with RCC....

Descripción completa

Detalles Bibliográficos
Autores principales:	Vogelzang, Nicholas J., Pal, Sumanta K., Ghate, Sameer R., Li, Nanxin, Swallow, Elyse, Peeples, Miranda, Zichlin, Miriam L., Meiselbach, Mark K., Perez, Jose Ricardo, Agarwal, Neeraj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397629/ https://www.ncbi.nlm.nih.gov/pubmed/29799328 http://dx.doi.org/10.18553/jmcp.2018.24.6.525

Ejemplares similares

Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis
por: Vogelzang, Nicholas J., et al.
Publicado: (2017)

Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis
por: Pilon, Dominic, et al.
Publicado: (2019)

Induction of trismus by sunitinib and pazopanib in metastatic renal cell carcinoma
por: Iyer, Ridhima, et al.
Publicado: (2017)

Correction: Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis
por: Pilon, Dominic, et al.
Publicado: (2021)

Factors involved in treatment preference in patients with renal cancer: pazopanib versus sunitinib
por: Mitchell, Catherine C, et al.
Publicado: (2014)

Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib
por: Gotink, Kristy J., et al.
Publicado: (2015)

Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells
por: Santoni, M, et al.
Publicado: (2013)

Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib
por: Fiala, Ondřej, et al.
Publicado: (2021)

Biological Role of Pazopanib and Sunitinib Aldehyde Derivatives in Drug-Induced Liver Injury
por: Maillard, Maud, et al.
Publicado: (2022)

The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line Treatment of Metastatic Renal Cell Carcinoma
por: Swallow, Elyse, et al.
Publicado: (2018)

IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma
por: Xu, C-F, et al.
Publicado: (2015)

Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom
por: Amdahl, Jordan, et al.
Publicado: (2017)

Efficacy of pazopanib and sunitinib in advanced axial chordoma: a single reference centre case series
por: Lipplaa, Astrid, et al.
Publicado: (2016)

Incidence and Economic Burden of Intertrochanteric Fracture: A Medicare Claims Database Analysis
por: Adeyemi, Ayoade, et al.
Publicado: (2019)

Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma
por: Bianconi, Maristella, et al.
Publicado: (2016)

Imatinib, sunitinib and pazopanib: From flat‐fixed dosing towards a pharmacokinetically guided personalized dose
por: Westerdijk, Kim, et al.
Publicado: (2020)

Real-World Treatment Patterns and Costs for Patients with Renal Cell Carcinoma Initiating Treatment with Sunitinib and Pazopanib
por: MacLean, Elizabeth, et al.
Publicado: (2016)

Metastatic Alveolar Soft Part Sarcoma Responsive to Pazopanib after Progression through Sunitinib and Bevacizumab: Two Cases
por: Read, William L., et al.
Publicado: (2016)

Sunitinib versus Pazopanib Dilemma in Renal Cell Carcinoma: New Insights into the In Vitro Metabolic Impact, Efficacy, and Safety
por: Amaro, Filipa, et al.
Publicado: (2022)

Treatment-related adverse effects with pazopanib, sorafenib and sunitinib in patients with advanced soft tissue sarcoma: a pooled analysis
por: Que, Yi, et al.
Publicado: (2018)

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
por: Amin, Asim, et al.
Publicado: (2018)

Sunitinib or Pazopanib: Is There Any Difference Between Tyrosine Kinase Inhibitors in the Pre-Nivolumab Setting in Metastatic Renal Cell Carcinoma?
por: Ucar, Gokhan, et al.
Publicado: (2020)

Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison
por: Signorovitch, James, et al.
Publicado: (2013)

Comparison of SEER Treatment Data With Medicare Claims
por: Noone, Anne-Michelle, et al.
Publicado: (2016)

P1738: A SEER-MEDICARE ANALYSIS OF THE ECONOMIC BURDEN AMONG ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH HYPOMETHYLATING AGENTS
por: McBride, A., et al.
Publicado: (2022)

Randomized Phase 2 Study of Trebananib (AMG 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib – Results of NCI/CTEP Protocol 9048
por: Semrad, Thomas J, et al.
Publicado: (2019)

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
por: Amin, Asim, et al.
Publicado: (2019)

Efficacy of First-Line Targeted Therapy in Real-World Korean Patients with Metastatic Renal Cell Carcinoma: Focus on Sunitinib and Pazopanib
por: Kim, Myung Soo, et al.
Publicado: (2018)

Analysis of Efficacy and Toxicity Profile of First-Line Sunitinib or Pazopanib in Metastatic Clear Cell Renal Cell Carcinoma in the Brazilian Population
por: Isaacsson Velho, Pedro, et al.
Publicado: (2018)

Physician Network Breadth and Plan Quality Ratings in Medicare Advantage
por: Sen, Aditi P., et al.
Publicado: (2021)

Disease-Specific Survival in De Novo Metastatic Renal Cell Carcinoma in the Cytokine and Targeted Therapy Era
por: Pal, Sumanta K., et al.
Publicado: (2013)

The Impact of Antipsychotic Dose Reduction on Clinical Outcomes and Health Care Resource Use Among Medicare Patients with Schizophrenia
por: Zichlin, Miriam L., et al.
Publicado: (2021)

The prevalence and burden of systemic lupus erythematosus in a medicare population: retrospective analysis of medicare claims
por: Garris, Cindy, et al.
Publicado: (2015)

Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First-Line Setting
por: Nikic, Predrag, et al.
Publicado: (2022)

Targeting Endoglin to Treat Metastatic Renal Cell Carcinoma: Lessons from Osler‐Weber‐Rendu Syndrome
por: Hahn, Andrew W., et al.
Publicado: (2018)

Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High‐Risk Prostate Cancer Followed by Radical Prostatectomy: A Phase II Randomized Trial
por: Maughan, Benjamin L., et al.
Publicado: (2018)

Linking individual medicare health claims data with work-life claims and other administrative data
por: Mokyr Horner, Elizabeth, et al.
Publicado: (2015)

Pazopanib in rare histologies of metastatic soft tissue sarcoma
por: Kataria, Babita, et al.
Publicado: (2021)

Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial
por: Guo, Jun, et al.
Publicado: (2018)

Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies
por: Sheng, Xinan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_h0u931n50jsdf1itu73goppm0t